Navigation Links
BioMarin to Present at the UBS Global Specialty Pharmaceuticals Conference
Date:5/18/2011

clinical development for the treatment of Pompe disease, and BMN-673, a poly ADP-ribose polymerase (PARP) inhibitor, which is currently in Phase I/II clinical development for the treatment of genetically-defined cancers. For additional information, please visit www.BMRN.com. Information on BioMarin's website is not incorporated by reference into this press release.

BioMarin®, Naglazyme®, Kuvan® and Firdapse™ are registered trademarks of BioMarin Pharmaceutical Inc.

Aldurazyme® is a registered trademark of BioMarin/Genzyme LLC.Contact:Investors

MediaEugenia Shen

Bob PurcellBioMarin Pharmaceutical Inc.

BioMarin Pharmaceutical Inc.(415) 506-6570

(415) 506-3267
'/>"/>

SOURCE BioMarin Pharmaceutical Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. BioMarin to Host First Quarter 2011 Financial Results Conference Call and Webcast on Thursday, April 28 at 5:00 p.m. ET
2. BioMarin to Host Third Quarter 2010 Financial Results Conference Call and Webcast on Thursday, October 28 at 5:00 p.m. ET
3. BioMarin to Present at the Barclays Capital Global Healthcare Conference
4. BioMarins Chief Executive Jean-Jacques Bienaime to Receive Most Admired CEO Award From San Francisco Business Times
5. BioMarin to Host Third Quarter 2009 Financial Results Conference Call and Webcast on Wednesday, October 28 at 5:00 p.m. ET
6. BioMarin to Present at the Morgan Stanley Healthcare Conference
7. BioMarin to Present at the Baird Healthcare Conference
8. BioMarin to Present at the Jefferies Healthcare Conference
9. BioMarin to Present at the Goldman Sachs Healthcare Conference
10. BioMarin to Present at the Deutsche Bank Health Care Conference
11. BioMarin to Present at the Baird Growth Stock Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/6/2015)... , May 6, 2015 ... anzukündigen, dass das Unternehmen einen mehrjährigen Vertrag ... dem das Unternehmen exklusiv für den Vertrieb ... 2 S) konventionellen und organischen Wein- und ... tritt ab sofort in Kraft. ...
(Date:5/6/2015)... , May 6, 2015 Bone Biologics, Corp., ("Bone ... with Hankey Capital, LLC ("Hankey Capital") of Los ... protein for use in bone regenerative medicine using the patented ... with patients undergoing spinal fusion. Michael ... with the completion of this round of funding which will ...
(Date:5/6/2015)... and ANN ARBOR, Mich. , May ... Robert Penny , CEO will give the keynote ... Repositories (ISBER) 2015 Annual Meeting in Phoenix, ... Dr. Penny,s talk, entitled "Personalized Medicine: The Odyssey" will focus ... over the past ten years in shaping our personalized ...
(Date:5/6/2015)... SHENZHEN, China , May 6, 2015 ... http://www.beikebiotech.com ) – Beike Biotechnology, the world,s ... ,high-dose, umbilical cord derived mesenchymal stem cell packets containing ... pack. This new product could significantly reduce the ... and therapies, especially in the case of degenerative ...
Breaking Biology Technology:Renaissance Yeast Inc. ernennt Quercus Europe, S.L. zum exklusiven Fachhändler für Schwefelwasserstoff-vermeidende Wein- und Mosthefen in Spanien 2Bone Biologics Corp Completes Financing With Hankey Capital, LLC 2Bone Biologics Corp Completes Financing With Hankey Capital, LLC 3Paradigm CEO Dr. Robert Penny Presents Keynote Address at 2015 ISBER Conference 2Paradigm CEO Dr. Robert Penny Presents Keynote Address at 2015 ISBER Conference 3Beike Biotechnology Produces High-dose Adult Stem Cell Packets for Degenerative Conditions 2
... and Product Offering , ... Rochester, ... a leading innovator in advanced cardiac safety biomakers and automated ... revenue growth as its quarter over quarter revenues have grown ...
... and OPAXIO Approval and CommercializationSEATTLE, Feb. 20 Cell ... that it exercised its option to sell its 50% ... Pharmaceuticals, Inc. (Spectrum) for $18 million. CTI and Spectrum ... and commercialize Zevalin. At that time CTI contributed all ...
... ABBOTT PARK, Ill., Feb. 20 The board of ... company,s quarterly common dividend 11 percent to 40 cents per ... increased its dividend payout and the 341st consecutive quarterly dividend ... dividend is payable May 15, 2009, to shareholders of record ...
Cached Biology Technology:iCardiac Reports Significant Revenue Growth and Profitability 2iCardiac Reports Significant Revenue Growth and Profitability 3Cell Therapeutics Exercises Its Option to Sell Interest in Zevalin Joint Venture to Spectrum Pharmaceuticals for $18 Million 2Cell Therapeutics Exercises Its Option to Sell Interest in Zevalin Joint Venture to Spectrum Pharmaceuticals for $18 Million 3Cell Therapeutics Exercises Its Option to Sell Interest in Zevalin Joint Venture to Spectrum Pharmaceuticals for $18 Million 4
(Date:5/6/2015)... 6, 2015 LifeBEAM, a developer of bio-sensing ... announced today that they will expand their partnership in ... bio-sensing cycling helmet and the first joint project between ... colors in order to give cyclists more style choices ... LifeBEAM and Lazer announced their plan to release a ...
(Date:5/5/2015)... May 5, 2015, NXT-ID, Inc. (NASDAQ: NXTD ... on the growing mobile commerce market, reminds investors and media ... Officer, is presenting  at CARTES SECURE CONNEXIONS AMERICA 2015, held ... The three-day conference is organized into a ... in is themed Global Fraud: Where is the Trust ...
(Date:4/27/2015)...  For more than four decades, AUVSI,s Unmanned ... premier worldwide event for the unmanned land, sea, and ... for any local, national, or trade news organization interested ... and current applications of unmanned technologies. The conference will ... billion industry, and how it will soon impact the ...
Breaking Biology News(10 mins):LifeBEAM and Lazer Announce Expanded Partnership in Bio-Sensing Sports Gear 2LifeBEAM and Lazer Announce Expanded Partnership in Bio-Sensing Sports Gear 3NXT-ID, Inc.'s CTO, David Tunnell, Presents at CARTES SECURE CONNEXIONS AMERICA 2015 Today in Washington DC. 2NXT-ID, Inc.'s CTO, David Tunnell, Presents at CARTES SECURE CONNEXIONS AMERICA 2015 Today in Washington DC. 3UNMANNED SYSTEMS 2015: Largest International Conference and Trade Show for the Drone and Unmanned Technology Industry 2UNMANNED SYSTEMS 2015: Largest International Conference and Trade Show for the Drone and Unmanned Technology Industry 3UNMANNED SYSTEMS 2015: Largest International Conference and Trade Show for the Drone and Unmanned Technology Industry 4UNMANNED SYSTEMS 2015: Largest International Conference and Trade Show for the Drone and Unmanned Technology Industry 5
... the German physician Paul Ehrlich coined the term Zuberkugel, or ... Magic bullets, also called silver bullets, because of the ... remain the goal of drug development efforts today. A ... currently working on a magic bullet for cancer, a disease ...
... developing a new hydrosurgery system to help physicians better manage excessive bleeding ... Oberdier, a Ph.D. candidate in ... help surgeons readily clear excess blood and control bleeding during critical stages ... "We are creating a ...
... assistant professor of engineering and science education Julie ... Faculty Early Career Development (CAREER) Award to study ... enter engineering fields. Trenor will use the ... capital to better understand undergraduate engineering students, academic ...
Cached Biology News:A golden bullet for cancer 2A golden bullet for cancer 3A golden bullet for cancer 4A golden bullet for cancer 5Clemson researcher receives grant to study engineering enrollment of women, minorities 2
Contained in EZ-Tn5™ Kits and are available separately for sequencing of an insertion site....
Immunogen: Tissue / cell preparation. (Murine EHS laminin preparation) Storage: -20 C, Avoid Freeze/Thaw Cycles...
Request Info...
Human Carnosine Dipeptidase 1 Affinity Purified PAb...
Biology Products: